Clinical Trial Update: Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of NNC172-2021 at two dose levels in healthy Japanese subjects; trial status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Bleeding Disorder
• Haemophilia

Drugs mentioned

• NNC172-2021

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED